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Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common subtypes of peripheral T-cell lymphoma.
Advances in understanding the mutational landscape of AITL have not resulted in improved prognosis nor consensus
regarding optimal first-line and second-line treatment.
The recently proposed multistep tumorigenesis model for AITL provides a theoretical framework of AITL oncogenesis.
In this model, early mutations in epigenetic modifiers interact with late cooperative mutations to enable malignant
transformation. Frequent mutations in epigenetic modifiers suggest that aberrant DNA methylation contributes to AITL
oncogenesis. Several research groups have reported findings suggesting that inappropriate costimulation acts as a late
cooperative mutation. Drugs targeting inappropriate costimulation have already been approved for the treatment of
several malignancies or autoimmune diseases. Additionally, aberrant DNA methylation was recently shown to potentiate
inappropriate costimulation in a subset of AITL cases. Therefore, drugs targeting inappropriate costimulation and
hypomethylating agents might have synergistic effects. Both offer promising new therapeutic options in AITL treatment.
This commentary summarizes the main findings on aberrant DNA methylation and inappropriate costimulation in AITL
and proposes several already approved drugs for AITL treatment. Hopefully, these will contribute to improving the still
dismal prognosis of AITL patients.
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Background
Peripheral T-cell lymphoma (PTCL) constitutes a hetero-
geneous group of non-Hodgkin lymphomas generally
characterized by an aggressive clinical course and poor
prognosis [1]. Angioimmunoblastic T-cell lymphoma
(AITL) is one of the most common subtypes of PTCL
accounting for 15–20% of all cases [2]. Advances in under-
standing the mutational landscape of AITL have not
resulted in improved prognosis over the last two decades
(5-year overall survival rate 25–41%), nor consensus
regarding optimal first-line and second-line treatment [3].
Recently, a multistep tumorigenesis model for AITL was
proposed [4]. In this model, early mutations in epigenetic
modifiers interact with late cooperative mutations to
enable malignant transformation. Frequent mutations in
epigenetic modifiers suggest aberrant DNA methylation is
involved in AITL oncogenesis. Several research groups
have reported findings suggesting inappropriate costimu-
lation acts as a late cooperative mutation in this model,
thereby significantly contributing to AITL oncogenesis
[5–8]. Drugs targeting inappropriate costimulation have
already been approved for the treatment of several malig-
nancies or autoimmune disorders. These drugs might be
potent new therapeutic options in AITL treatment.
Additionally, it was recently shown that aberrant DNA
methylation is able to potentiate inappropriate costimula-
tion [9]. These findings support the simultaneous use of
hypomethylating agents and drugs targeting inappropriate
costimulation in a subset of AITL cases. As these insights
provide us with several new therapeutic options for AITL
treatment, the efficacy of these already approved drugs
should be evaluated in pre-clinical and clinical trials.* Correspondence: mathijs.willemsen@student.maastrichtuniversity.nl
Department of Internal Medicine, Division of Hematology, Maastricht
University Medical Centre, PO Box 58006202, AZ, Maastricht, The Netherlands
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Willemsen and Schouten Biomarker Research  (2017) 5:6 
DOI 10.1186/s40364-017-0085-8
Aberrant DNA methylation and multistep tumorigenesis
in AITL
Varies sequencing studies have been conducted to inves-
tigate the mutational landscape of AITL. TET2, IDH2
and DNMT3A are mutated in 30–80%, 20–45% and
10–30% of investigated AITL cases, respectively [9–17].
Because all these genes encode epigenetic modifiers, it is
suspected that aberrant DNA methylation somehow
contributes to AITL oncogenesis.
Ten-Eleven Translocation 2 (TET2) is a Fe2+- and
2-oxoglutarate (2OG)-dependent dioxygenase involved
in DNA demethylation. Most cytosine derivatives generated
by TET2, especially 5-hydroxymethylcytosine resulting in
DNA hydroxymethylation, are stable epigenetic marks [18].
Precisely how mutant TET2 contributes to AITL
oncogenesis is unclear, but experimental data has
shown that hematopoietic stem cells (HSCs) are particu-
larly vulnerable to disruption of TET2 function resulting
in increased self-renewal capacity and altered terminal
differentiation [18]. Additionally, it was recently shown
that intron1 of the BCL6 gene is frequently hypermethy-
lated in mutant TET2 AITL cases [19]. B cell lymphoma 6
(Bcl6) is considered to be the lineage defining transcrip-
tion factor for T follicular helper cells (TFH) [20]. Intron1
of the BCL6 gene has been identified as a silencer region,
working in a methylation-sensitive manner in lymphoma
cell lines [21]. Accordingly, Bcl6 was overexpressed in
mutant TET2 AITL cases [19]. Similar results regarding
BCL6 intron1 methylation and transcriptional upregula-
tion have been reported in a TET2-knockdown mouse
model which eventually develops T-cell lymphoma with
TFH-like features [22]. Deregulated Bcl6 expression poten-
tially alters TFH differentiation and renders affected cells
susceptible for malignant transformation after acquiring
late cooperative mutations. Isocitrate dehydrogenase 2
(IDH2) is a potential regulator of TET2. Wildtype IDH2
catalyzes the two-step interconversion of isocitrate to
2OG. Mutant IDH2, in AITL restricted to R172 residue
mutations, catalyzes the reduction of 2OG to (R)-2-hydro-
xyglutarate (2HG). 2HG has been identified as an
oncometabolite potentially contributing to malignant
transformation by competitively inhibiting 2OG-
dependent enzymes. As these enzymes are involved in
many cellular functions including DNA and histone
modification, cellular energy metabolism and differen-
tiation, further research is warranted to evaluate the
oncogenic potential of downstream targets of mutant
IDH2 [23]. A recent report further explored the role
of mutant IDH2 in AITL. Tumor biopsies of nine
untreated AITL patients only carried mutant IDH2 in
the T-cell compartment, indicating that this mutation
occurs in mature T-cells and not in HSCs [24]. Using
a conditional knock-in mouse model the researchers
investigated the effects of several IDH2 mutations
in vivo. The R172 mutation, which is almost exclusively
encountered in AITL, produced significantly more 2HG
in the hematopoietic system than mutations at other
residues. Additionally, the researchers found that only the
R172 mutation impaired lymphoid development and
inhibited TET2 function resulting in decreased DNA
hydroxymethylation [24]. How this altered DNA hydroxy-
methylation pattern contributes to AITL oncogenesis is
unknown. The greater 2HG generating capacity of the
R172 mutations in lymphoid cells compared to mutations
at other residues might explain why this mutation is
exclusively found in AITL. Furthermore, the ability of the
R172 mutation to inhibit TET2 function in vivo suggest a
synergetic effect of both mutations in AITL oncogenesis.
Wang et al. recently showed that mutant IDH2 is associ-
ated with hypermethylation of specific genes in AITL [9].
Among downregulated genes were negative regulators of
T-cell signaling (PTPN7, SIT1 and DGKA). Protein tyro-
sine phosphatase non-receptor type 7 (PTPN7), also called
hematopoietic PTP, is a mitogen-activated protein kinase
(MAPK)-specific tyrosine phosphatase. PTPN7 inhibits T
cell activation by dephosphorylating specific residues of
MAPKs thereby preventing further downstream signaling
along the Ras/Raf/MAPK/extracellular signal-regulated
kinase (ERK) pathway [25]. SIT1 is a transmembrane
adaptor protein involved in immune cell activation. SIT1
negatively regulates T cell activation by sequestering
signaling molecules (e.g. Grb2) thereby preventing them
from being recruited to the activated T cell receptor. This
in turn prevents activation of downstream signaling
pathways such as the Ras/Raf/MAPK/ERK pathway and
thus T cell activation [26]. Diacylglycerol kinase alpha
(DGKα) is a lipid kinase which converts diacylglycerol to
phosphatidic acid, both important second messengers in
several intracellular signaling pathways including Ras/Raf/
MAPK/ERK and phosphatidylinositol 3 kinase (PI3K)/
Akt/mammalian target of rapamycin (mTOR) signaling
pathways. Whereas one might reason that DGKα inhib-
ition would deplete second messengers and dampen
signaling through these signaling pathways, evidence
suggests the opposite is true. DGKα inhibition
counterintuitively increases Ras activation and also T cell
activation. It is therefore suspected that the in vivo effects
of DGKα inhibition vary among different cell types [27].
As the evidence suggests that hypermethylation and sub-
sequent downregulation of PTPN7, SIT1 and DGKα can
potentially increase signaling through the Ras/Raf/MAPK/
ERK pathway, it is possible that these epigenetic changes
contribute to deregulated T cell activation and AITL
oncogenesis. DNA methyltransferase 3A (DNMT3A)
mediates de novo DNA methylation, a process which is
relatively poorly understood. Experimental data has shown
that loss of DNMT3A function results in impaired HSC
differentiation and expansion of the HSC pool in the bone
Willemsen and Schouten Biomarker Research  (2017) 5:6 Page 2 of 8
marrow. On methylation analysis, daughter cells exhibit
global DNA hypomethylation and hypermethylation of
specific CpG islands resulting in downregulation of early
differentiation factors and upregulation of stem cell asso-
ciated multipotency genes [28, 29]. It seems affected cells
are skewed towards self-renewal instead of differentiation.
This increased proliferative capacity likely contributes to
AITL oncogenesis when affected cells acquire additional
cooperative mutations. Interestingly, 70–100% of AITL
patients with DNMT3A mutations also have TET2 muta-
tions [9–17]. It was recently shown that co—occurrence
of loss of function of TET2 and DNMT3A R882H muta-
tion is able to drive the development of lymphoid malig-
nancies, including AITL-like disease, in mice [30]. These
data imply that DNMT3A and TET2 mutations have
synergistic effects in AITL oncogenesis. As previously
explained, both DNMT3A and TET2 potentially render
HSCs susceptible for malignant transformation. Unfortu-
nately, no DNA methylation analysis was performed on
AITL-like mice. In addition to frequent mutations in
epigenetic modifiers, RHOA is mutated in 50–70% of
investigated AITL cases [9, 11, 12, 14]. Ras homologue
family member A (Rhoa) is part of a subgroup of the Ras
superfamily of GTP hydrolases. In the vast majority of
AITL cases a missense mutation causes G17V substitution
in the GTP/GDP-binding domain. Functional studies
showed mutant Rhoa to act as a dominant-negative signal-
ing protein, moderately increasing cell proliferation by
increasing Akt phosphorylation [9, 11, 12, 14]. Recently,
researchers generated a conditional knock-in mouse
model which selectively induces mutant Rhoa expression
in CD4+ T-cells [31]. Expression of mutant Rhoa resulted
in spontaneous accumulation of TFH with both increased
expression of the Inducible T-cell CoStimulator (ICOS)
receptor and increased ICOS-dependent signaling. Block-
ing ICOS signaling using an anti-ICOS antibody pre-
vented mutant Rhoa-induced TFH phenotype [31]. ICOS
is a relatively new costimulatory molecule belonging to
the immunoglobulin family of co-receptors, as does the
relatively old costimulatory molecule CD28. ICOS is not
constitutively expressed on naïve T-cells, rather its ex-
pression is induced by activation of T-cell receptor sig-
naling and/or CD28 activation. ICOS signaling has
shown to play a critical role in promoting the TFH
phenotype, likely via stabilization of Bcl6 [32]. It seems
expression of mutant Rhoa in naïve T-cells induces TFH
phenotype via increased ICOS signaling. This mechan-
ism might explain why this mutation is so frequently
encountered in AITL.
Mutations in TET2 and DNMT3A are not only found
in AITL but also in myeloid malignancies and even
non-malignant HSCs. It is currently presumed that these
mutations are acquired during an early stage of
hematopoietic differentiation. Mutant HSCs cause clonal
hematopoiesis and eventually give rise to preleukemic/
prelymphoma stem cells with an increased risk for sub-
sequent hematologic malignancies [33]. What kind of
malignancy develops depends upon the pattern of
acquired late cooperative mutations. It is currently sus-
pected that mutations in RHOA and IDH2 are acquired
at a later stage and contribute to AITL development
from prelymphoma stem cells [4]. The first line of
evidence validating the multistep tumorigenesis model
for AITL has recently been published. The same re-
search group that showed the TFH phenotype-inducing
capacities of mutant Rhoa in vivo, also explored the
potentially synergistic effect of mutations in TET2 and
RHOA. Expression of mutant Rhoa in HSCs derived
from TET2-deficient mice resulted in the development
of AITL. Neoplastic cells were heavily dependent upon
ICOS signaling for growth and proliferation in vivo [31].
These are the first data to support the oncogenic poten-
tial of mutations in epigenetic modifiers interacting with
cooperative mutations. Identifying additional cooperative
mutations will increase our understanding of AITL
oncogenesis and might offer new therapeutic options.
T cell activation and evidence for inappropriate
costimulation
T cell activation is determined by engagement of co-
stimulatory and co-inhibitory molecules in combination
with T cell receptor activation. As binding affinity of
co-inhibitory molecules is generally higher compared to
co-stimulatory molecules, T cell activation is mitigated
when expression of ligands is low. This interplay
functions to ensure appropriate T cell activation [34].
Engagement of co-stimulatory molecule CD28 by its
ligands CD80 or CD86 initiates several intracellular sig-
naling pathways via association of kinases and adaptor
proteins to its cytoplasmic domains. These intracellular
signaling pathways eventually culminate in activation of
transcription factors (e.g. NF-AT, AP-1 and NF-κB)
essential for T cell survival, proliferation and protein
synthesis [35]. The PI3K/Akt/mTOR and Ras/Raf/MAPK/
ERK intracellular signaling pathways are among the best
studied signaling pathways downstream of CD28 [34].
Two research groups identified missense mutations in
the gene encoding co-stimulatory molecule CD28 [5, 6].
Mutations at residue T195 and D124 were identified in
5-11% of investigated AITL cases. Using wildtype and
mutant CD28-transfected cells both research groups
explored the functional significance of these mutations.
Binding affinity of CD28 D124V for CD86 was two times
higher compared to wildtype CD28. The CD28 T195P
mutant showed decreased binding affinity for PI3K regu-
latory heterodimer p85/p110, but increased binding
affinity for adaptor proteins Grb2 and GRAP2. In CD28
T195P mutant-tranfected cells phosphorylation of
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downstream signaling proteins Akt, mTOR and ERK
and proliferation rate were increased compared to wild-
type CD28-transfected cells, either with or without
stimulation. These findings are in line with the concept
that mutant CD28 is constitutively active and promotes
T cell proliferation. Both research groups confirmed
enhanced NF-κB signaling in mutant CD28-tranfected
cells compared to wildtype after stimulation [5, 6]. Gene
expression profiling found increased T cell signal trans-
duction signature in mutant CD28-positive AITL cases
compared to wildtype CD28 cases [6]. Additionally,
mutant CD28-positive AITL cases showed decreased
overall survival compared to wildtype cases [6]. These
finding are in accordance with a previous report showing
decreased overall survival in AITL and PTCL not other-
wise specified cases with activation of NF-κB signaling
[36]. Yoo et al. reported the presence of a CTLA4-CD28
fusion gene in 58% of investigated AITL cases in an
Asian cohort. [7]. The corresponding fusion protein con-
sists of the extracellular and transmembrane domains of
co-inhibitory molecule cytotoxic T-lymphocyte antigen-
4 (CTLA-4) and the cytosolic domain of co-stimulatory
molecule CD28. This suggests that the fusion protein
can bind ligands with the affinity of CTLA-4 while
mediating the T cell activating effects of CD28. Indeed,
functional study of fusion gene-transfected cells showed
increased phosphorylation of Akt and ERK and increased
proliferation rate compared to CTLA-4 wildtype-
transfected cells on stimulation [7]. The effect of CTLA4-
CD28 fusion protein activation on NF-κB signaling or
gene expression has not been assessed. Yoo et al. did
however evaluate the mutational landscape in which the
fusion gene occurred. The frequency of the CTLA4-CD28
fusion gene was 38% (11/29) in deep sequenced AITL
cases. None of the fusion gene-positive AITL cases carried
a mutation in CD28, whereas 22% (4/18) of fusion gene-
negative AITL cases did carry a C28 mutation [7]. These
data suggest that occurrence of the CTLA4-CD28 fusion
gene and CD28 mutations are mutually exclusive. In sum-
mary, both CD28 mutations and CTLA4-CD28 fusion
increases intracellular signaling downstream of CD28 via
PI3K/Akt/mTOR and Ras/Raf/MAPK/ERK signaling
pathways resulting in increased survival and proliferation.
Together these in vitro studies provide strong evidence
for inappropriate costimulation as potential driver of
AITL oncogenesis. In the multistep tumorigenesis model
for AITL, inappropriate costimulation would therefore
classify as a cooperative mutation which potentially
contributes to AITL development from prelymphoma
stem cells.
A recently published study expanded upon these earlier
findings indicating inappropriate costimulation as poten-
tial cooperative mutation in AITL oncogenesis. Vallois et
al. showed that 50% (36/72) of investigated AITL cases
had mutations in components of T cell receptor signaling
or costimulatory pathways, other than RHOA [8]. Intri-
guingly, these mutations had a nearly mutually exclusive
nature thereby confirming the findings by Yoo et al. [7].
CD28 was mutated in 11% (8/72) of investigated AITL
cases. Additionally, several components of both the PI3K/
Akt/mTOR and Ras/Raf/MAPK/ERK signaling pathways
were mutated. The vast majority of mutations were classi-
fied as gain-of-function. Enrichment analysis of AITL
cases with mutations in T cell receptor signaling or costi-
mulatory pathways compared to AITL cases without such
mutations showed significantly enriched molecular signa-
tures reflecting activation of several signaling pathways
including PI3K and NF-κB. These findings are in line with
previous reports showing increased activation NF-κB
signaling in mutant CD28 AITL cases [5, 6]. The nearly
mutually exclusive nature of these mutations implies that
a single gain-of-function mutation in T cell receptor
signaling or costimulatory pathways, which are regarded
as essential for T cell survival and are tightly regulated
under physiological conditions, is sufficient to contribute
to full blown malignant transformation in a subset of
AITL cases. Together, these data underline inappropriate
costimulation as cooperative mutation and significant
contributor to AITL oncogenesis.
Targeting inappropriate costimulation
Targeting inappropriate costimulation in AITL might
prove an effective therapeutic approach. Two strategies
could potentially be effective in blocking inappropriate
costimulation: 1) preventing ligand-coreceptor interaction
and 2) inhibition of intracellular signaling pathways down-
stream of co-stimulatory molecule CD28 (Fig. 1).
Various drugs targeting ligand-coreceptor interaction
have already been approved. Ipilimumab (Yervoy;
Bristol-Myers Squibb) is a CTLA-4-specific monoclonal
antibody which can potentially be effective in CTLA4-
CD28 fusion gene-positive AITL patients. Ipilimumab has
already been approved for the treatment of malignant
melanoma [37]. Abatacept (Orencia; Bristol-Myers
Squibb) and belatacept (Nulojix; Bristol-Myers Squibb),
both CTLA4-immunoglobulin fusion proteins, are able to
bind coreceptor ligands CD80 and CD86, thereby prevent-
ing activation of mutant CD28 or the CTLA4-CD28
fusion protein. Abatacept is already approved for the treat-
ment of rheumatoid arthritis, whereas belatacept is ap-
proved for prevention of kidney transplant rejection [38].
Various components of the PI3K/Akt/mTOR signaling
pathway have been targeted by specific inhibitors. Idela-
lisib (Zydelig; Gilead Sciences) inhibits class I PI3K
isoform p110δ, the main PI3K isoform expressed in
leukocytes. Idelalisib is already approved for the treatment
of certain hematological malignancies (e.g. follicular B-cell
non-Hodgkin lymphoma). In vitro data has shown that
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p110δ is the main PI3K isoform responsible for PI3K
activity at the immune synapse [39]. Because mutant
CD28 has decreased binding affinity for PI3K regulatory
heterodimer p85/p110, it remains to be seen if inhibiting
p110δ has an anti-proliferative effect in mutant CD28
AITL cases. However, a previous report has shown that
CD28 can enhance PI3K activity independently of its
capacity to interact with the p85/p110 heterodimer [39].
Potentially mutant CD28 activates PI3K via other mecha-
nisms. Therefore, combined targeting of CD28 and class I
PI3K isoform p110δ might prove a potent therapeutic
option in mutant CD28 AITL cases. Idelalisib as a single
agent, or in combination with a CTLA-4 blocker, could
also be effective in CTLA4-CD28 fusion gene-positive
AITL cases. Furthermore, two mTOR inhibitors, everoli-
mus (Afinitor; Novartis) and temsirolimus (Torisel;
Pfizer), have been approved for the treatment of renal cell
carcinoma. Temsirolimus has also been approved for the
treatment of relapsed/refractory (R/R) mantle cell lymph-
oma. Both agents initially only inhibit the mTORC1 pro-
tein complex and not the mTORC2 complex, whereas
CD28 costimulation has shown to induce both mTORC1-
and mTORC2-dependent signaling [40]. In vitro data has
shown that prolonged exposure to rapamycin impairs
mTORC2 complex assembly in certain cell types, includ-
ing Jurkat and BJAB cells [41]. It is likely that everolimus
and temsirolimus, both rapamycin analogs, exert the same
cell-dependent effect on mTORC2. As both mutant CD28
and CTLA4-CD28 fusion gene-transfected cells showed
increased phosphorylation of mTOR, prolonged exposure
to mTOR inhibitors might prove a potent therapeutic
option in mutant CD28 and CTLA4-CD28 fusion gene-
positive AITL cases. A recent phase II clinical trial on the
treatment of newly diagnosed PTCL patients with
Fig. 1 Potential inhibitors of inappropriate costimulation in AITL. CD28 is a costimulatory molecule essential for proper T cell activation. CD80/CD86
binding initiates several intracellular signaling pathways via association of kinases and adaptor proteins to its cytoplasmic domains. These in turn
activate several intracellular signaling pathways (e.g. PI3K/Akt/mTOR and Ras/Raf/MAPK/ERK) resulting in proliferation, activation and differentiation and
protein synthesis. CTLA-4 is a co-inhibitory molecule mitigating T cell activation. In general, CTLA-4 inhibits T cell activation by three mechanisms:
competition for ligand binding, diminution of intracellular signaling protein recruitment and direct inhibition of downstream signaling pathways. Both
mutant CD28 and the CTLA4-CD28 fusion protein mediate inappropriate costimulation potentially driving proliferation of malignant cells in AITL. Various
already approved drugs can potentially block inappropriate costimulation by preventing ligand-coreceptor interaction or inhibiting the PI3K/Akt/mTOR and
Ras/Raf/MAPK/ERK signaling pathways. Red arrows: activation, Blue dots: inhibition
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everolimus and CHOP showed complete response in all
included AITL cases (3/3) [42]. The mutational landscape
of included AITL patients is unknown. It is suspected that
mTOR-dependent signaling plays a role in TFH differenti-
ation which could also explain the efficacy of everolimus
in AITL [43].
Most of the approved Ras/Raf/MAPK/ERK signaling
pathway inhibitors target frequently mutated components.
Sorafenib (Nexavar; Bayer), a multikinase inhibitor (in-
cluding Raf), and trametinib (Mekinist; GlaxoSmithKline)
and cobimetinib (Cotellic; Genentech/Exelixis), both MEK
inhibitors, are currently the only approved non-BRAF
mutant-selective Ras/Raf/MAPK/ERK signaling pathway
inhibitors [44]. Sorafenib is approved for the treatment of
renal cell carcinoma, hepatocellular carcinoma and
thyroid carcinoma, whereas trametinib and cobimetinib
are approved for the treatment of malignant melanoma. It
is likely that activation of mutant CD28 results in
increased Raf and MEK phosphorylation due to increased
binding affinity for upstream Grb2 and GRAP2 and
increased phosphorylation of downstream ERK [5, 6].
Activation of CTLA4-CD28 fusion protein also re-
sulted in increased ERK phosphorylation [7]. These
agents might therefore be a potent therapeutic option
in mutant CD28 and CTLA4-CD28 fusion gene-
positive AITL cases.
Combined targeting of inappropriate costimulation and
aberrant DNA methylation
TET2 and DNMT3A are among the most frequently
mutated genes in AITL [9–17]. The multistep tumori-
genesis model for AITL focuses on the interaction
between early mutations in these epigenetic modifiers
and late cooperative mutations enabling malignant
transformation [4]. As previously explained, a growing
body of evidence suggests that aberrant DNA methyla-
tion predisposes to malignant transformation. Despite
availability and experience with hypomethylating agents
in other hematological diseases, targeting aberrant DNA
methylation is not part of current AITL treatment.
Azacitidine (Vidaza; Celegene) and decitabine (Dacogen;
Otsuka) are currently the only two approved hypomethy-
lating agents for the treatment of myelodysplastic
syndromes and acute myeloid leukemia [45]. Azacitidine
and decitabine are nucleoside analogues that incorporate
into newly synthesized DNA and RNA strands and irre-
versibly inhibit DNMTs. Both drugs primarily inhibit
DNMT1, which is responsible for maintaining DNA
methylation patterns after DNA replication [46]. Loss of
DNMT1 function results in DNA hypomethylation and
potentially prevents the aberrant DNA methylation pat-
tern in AITL from being epigenetically inherited by
daughter cells. DNMT3A is only inhibited at higher doses
of azacitidine in vitro [46]. Two case reports have shown
promising response of R/R AITL patients when treated
with azacitidine [47, 48]. Both patients carried TET2 mu-
tations and achieved complete response. Additionally, a
recent report on 12 R/R AITL patients being treated with
azacitidine, including both previously published case re-
ports, showed an overall response and complete response
rate of 75 and 42%, respectively [49]. Only two of the ini-
tial responders experienced disease progression after 86
and 499 days. Intriguingly, all initial responders with avail-
able TET2 mutational status had TET2 mutations (8/8).
Additional DNA sequencing studies are undergoing to
further investigate the mutational landscape of included
AITL cases. Further prospective data are needed to con-
firm these findings, but it is clear that targeting aberrant
DNA methylation in AITL is a promising therapeutic
option.
Combined targeting of inappropriate costimulation
and aberrant DNA methylation may prove to increase
therapeutic efficacy in some AITL cases. Several negative
regulators of T cell receptor signaling (PTPN7, SIT1 and
DKGA) have shown to be hypermethylated and down-
regulated in mutant IDH2 AITL cases [9]. As previously
explained, downregulation of these genes could poten-
tially lead to increased signaling through the Ras/Raf/
MAPK/ERK pathway downstream of mutant CD28 or
the CTLA4-CD28 fusion protein, thereby potentiating
inappropriate costimulation and contributing to AITL
oncogenesis [25–27]. The various targets of negative
regulators of T cell receptor signaling are located at mul-
tiple levels downstream of mutant CD28 and the
CTLA4-CD28 fusion protein. This suggests that only
targeting inappropriate costimulation at a single level by
using the proposed drugs is insufficient to completely
abolish inappropriate costimulation. We hypothesize
that the use of hypomethylating agents in mutant IDH2
AITL cases induces DNA hypomethylation, thereby re-
storing expression of the negative regulators of T cell re-
ceptor signaling and subsequently abolishing their
potentiating effect on inappropriate costimulation. If in-
appropriate costimulation is simultaneously targeted,
this potentially eradicates signaling through costimula-
tory pathways. The recent findings by Vallois et al.,
showing that 50% of investigated AITL cases had muta-
tions in components of T cell receptor signaling or costi-
mulatory pathways, highlight the importance of
deregulated signaling through costimulatory pathways,
including the Ras/Raf/MAPK/ERK pathway, in AITL
oncogenesis [8]. Together with the fact that aberrant
DNA methylation contributes to AITL oncogenesis,
these findings provide a strong biological and theoretical
rationale for the simultaneous use of hypomethylating
agents and drugs targeting inappropriate costimulation
in mutant IDH2 AITL cases with mutations in costimu-
latory pathways.
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Conclusion
Advances in understanding the mutational landscape of
AITL have not resulted in improved prognosis nor
consensus regarding optimal first-line and second-line
treatment. However, these findings have resulted in a
multistep tumorigenesis model for AITL which provides
us with a theoretical framework for AITL oncogenesis.
Several research groups have identified mutations in
costimulatory pathways resulting in inappropriate costi-
mulation, potentially contributing to AITL oncogenesis.
We propose that inappropriate costimulation can be
regarded as a new cooperative mutation for AITL devel-
opment from prelymphoma stem cells. This insight
opens new therapeutic options for AITL treatment. We
have proposed several candidate drugs with the potential
to block inappropriate costimulation which have already
been approved for the treatment of other malignancies
or autoimmune disorders. Furthermore, we provided an
overview of the current knowledge regarding aberrant
DNA methylation in AITL. Hypomethylating agents are
already being used to treat other hematological disorders
and first prospective data for the use of hypomethylating
agents in AITL treatment are promising. Additionally,
studies have shown that aberrant DNA methylation can
increase signaling through costimulatory pathways and
therefore potentiate inappropriate costimulation. To-
gether with the fact that aberrant DNA methylation con-
tributes to AITL oncogenesis, these findings provide a
biological and theoretical rationale for the simultaneous
use of hypomethylating agents and drugs targeting
inappropriate costimulation in a subset of AITL cases.
Pre-clinical studies and clinical trials should be readily
conducted to investigate the efficacy of these already
approved drugs and their potential synergistic effect.
Hopefully, these insights will contribute to improving
the still dismal prognosis of AITL patients.
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